Ron Korn

1.0k total citations
26 papers, 350 citations indexed

About

Ron Korn is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Ron Korn has authored 26 papers receiving a total of 350 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Molecular Biology. Recurrent topics in Ron Korn's work include Radiomics and Machine Learning in Medical Imaging (7 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Ron Korn is often cited by papers focused on Radiomics and Machine Learning in Medical Imaging (7 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Ron Korn collaborates with scholars based in United States, Germany and Australia. Ron Korn's co-authors include Daniel D. Von Hoff, Spyro Mousses, Michael S. Gordon, Susan J. Knox, Bryan Oronsky, Ramesh K. Ramanathan, Ian A. Wilson, Michael D. Farwell, Matthew D. Hellmann and Alessandro Mascioni and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Cell and Cancer Research.

In The Last Decade

Ron Korn

24 papers receiving 347 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ron Korn United States 8 206 104 83 71 68 26 350
Sara Chiblak Germany 8 190 0.9× 141 1.4× 78 0.9× 48 0.7× 109 1.6× 12 394
Shih‐Hung Yang Taiwan 11 286 1.4× 114 1.1× 128 1.5× 70 1.0× 60 0.9× 37 412
Giacomo Barchiesi Italy 11 232 1.1× 108 1.0× 88 1.1× 44 0.6× 96 1.4× 22 376
Mohamed M. Kahila United States 7 205 1.0× 126 1.2× 121 1.5× 49 0.7× 65 1.0× 15 373
Ningning Dong China 11 178 0.9× 194 1.9× 142 1.7× 99 1.4× 93 1.4× 20 479
Andrew Cannon United States 10 245 1.2× 252 2.4× 79 1.0× 51 0.7× 50 0.7× 24 501
Qing Jiang China 7 130 0.6× 104 1.0× 74 0.9× 42 0.6× 71 1.0× 12 292
Tongguo Si China 13 153 0.7× 75 0.7× 90 1.1× 57 0.8× 146 2.1× 29 405
Aiko Nagayama Japan 9 274 1.3× 74 0.7× 100 1.2× 97 1.4× 92 1.4× 27 394

Countries citing papers authored by Ron Korn

Since Specialization
Citations

This map shows the geographic impact of Ron Korn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ron Korn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ron Korn more than expected).

Fields of papers citing papers by Ron Korn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ron Korn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ron Korn. The network helps show where Ron Korn may publish in the future.

Co-authorship network of co-authors of Ron Korn

This figure shows the co-authorship network connecting the top 25 collaborators of Ron Korn. A scholar is included among the top collaborators of Ron Korn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ron Korn. Ron Korn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chung, Vincent, Angela Alistar, Carlos Becerra, et al.. (2025). Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. The Oncologist. 30(1). 4 indexed citations
2.
3.
Vachon, Celine M., Ran Jiang, Jack Youngren, et al.. (2024). 70MO Cell-free DNA indicates potential preclinical detectability of cancer signals up to 30 months prior to diagnosis. Annals of Oncology. 35. S242–S242. 1 indexed citations
4.
Schwenck, Johannes, Dominik Sonanini, Walter Ehrlichmann, et al.. (2023). In vivo imaging of CD8+ T cells in metastatic cancer patients: first clinical experience with simultaneous [89Zr]Zr-Df-IAB22M2C PET/MRI. Theranostics. 13(8). 2408–2423. 10 indexed citations
5.
Schwenck, Johannes, Dominik Sonanini, Walter Ehrlichmann, et al.. (2022). Abstract LB058: Imaging of CD8+ cytotoxic T-cells by Zr-89-Df-IAB22M2C PET/MRI: First clinical experience in patients with metastatic cancer. Cancer Research. 82(12_Supplement). LB058–LB058. 1 indexed citations
6.
7.
Borazanci, Erkut, Erika Hamilton, Jacob Thomas, et al.. (2022). A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 3097–3097. 3 indexed citations
8.
Farwell, Michael D., Matthew D. Hellmann, James J. Harding, et al.. (2021). CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of 89Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody. Journal of Nuclear Medicine. 63(5). jnumed.121.262485–jnumed.121.262485. 80 indexed citations
9.
Korn, Ron, Rajesh Gulati, Gordon J. Harris, et al.. (2020). Comparative analysis of three-dimensional volume rendering and maximum intensity projection for preoperative planning in liver cancer. European Journal of Radiology Open. 7. 100259–100259. 7 indexed citations
10.
Kardan, Arash, David Ralph, Michael Rosol, et al.. (2019). A Phase I/Phase II Study of Intravenously (IV) Administered Tc 99m Tilmanocept (TCT) to Determine Safety, Tolerability, Optimal Clinical Dose Selection, and Imaging Timepoint in Patients Clinically Diagnosed with Rheumatoid Arthritis (RA). 60. 89–89. 1 indexed citations
11.
Fernández-Zapico, Martín E., Dae Won Kim, Philip Philip, et al.. (2019). Abstract B15: Therapeutic potential of targeting amino acid metabolism in pancreatic cancer. Cancer Research. 79(24_Supplement). B15–B15. 2 indexed citations
12.
Chaudhry, Ammar, Behnam Badie, Rahul Jandial, et al.. (2018). Utility of Functional MRI and 3D Tractography in Presurgical Planning in Patients with Glioblastoma. 4(6). 1 indexed citations
13.
Beeram, M., E.P. Hamilton, Mariela Blum Murphy, et al.. (2017). Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers. Annals of Oncology. 28. v82–v82. 4 indexed citations
14.
15.
Reid, Tony, Bryan Oronsky, Jan Scicinski, et al.. (2015). Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. The Lancet Oncology. 16(9). 1133–1142. 76 indexed citations
16.
17.
Ramanathan, Ramesh K., Ron Korn, Jasgit C. Sachdev, et al.. (2014). 261 Lesion characterization with ferumoxytol MRI in patients with advanced solid tumors and correlation with treatment response to MM-398, nanoliposomal irinotecan (nal-IRI). European Journal of Cancer. 50. 87–87. 6 indexed citations
18.
Fleishon, Howard B., et al.. (2011). The Clinical Research Center: A Vital Part of the ACR Mission. Journal of the American College of Radiology. 8(6). 422–427. 2 indexed citations
19.
Hoff, Daniel D. Von, Ron Korn, & Spyro Mousses. (2009). Pancreatic Cancer—Could It Be that Simple? A Different Context of Vulnerability. Cancer Cell. 16(1). 7–8. 30 indexed citations
20.
Korn, Ron, et al.. (2002). [Primary cancer of the liver in children; 7 case reports].. PubMed. 1(4). 514–47.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sara Chiblak Breakdown of academic impact, for papers by Shih‐Hung Yang Breakdown of academic impact, for papers by Giacomo Barchiesi Breakdown of academic impact, for papers by Mohamed M. Kahila Breakdown of academic impact, for papers by Ningning Dong Breakdown of academic impact, for papers by Andrew Cannon Breakdown of academic impact, for papers by Qing Jiang Breakdown of academic impact, for papers by Tongguo Si Breakdown of academic impact, for papers by Aiko Nagayama
Rankless by CCL
2026